The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.
Welcome to The Lymphoma Channel
Hodgkin lymphoma is a malignancy of lymphocytes. Approximately half of all cases are due to the Epstein-Barr virus (EBV) of which being HIV positive is also a risk factor.
Hodgkin lymphoma can be divided into two subtypes, classical and nodular lymphocyte-predominant Hodgkin lymphoma.
The majority of classical Hodgkin lymphoma is composed of a mixed inflammatory infiltrate composed of lymphocytes, eosinophils, fibroblasts, macrophages and plasma cells as opposed to the classical Reed-Sternberg cells. Nodular, lymphocyte-predominant Hodgkin lymphoma is a rare entity and accounts for less than 5% of cases.
It is characterized by the presence of lymphocyte-predominant cells which expressed CD20, CD79a, and EMA but not CD30 or CD15 which is expressed in the classical type. Overall, Hodgkin lymphoma has a high cure rate and overall survival. However, exposure to radiation and chemotherapy in those patients diagnosed at a young age increases their risk of other malignancies later in life.
The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys.
The supporters have no influence over the production of the content.
If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.
